Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Endologix, Inc.
A pair of new PwC reports project a more robust M&A environment in 2023, but questions about the impact of the Inflation Reduction Act are already affecting biopharma business development strategies.
The US FDA released updated safety information on Endologix Inc.’s AFX2 Endovascular abdominal aortic aneurysm (AAA) graft system on Tuesday. Previous devices in the product line have been associated with an increased risk of abnormal bleeding.
Codagenix hopes a 2023 data readout from its intranasal RSV vaccine will be an inflection point, even as GSK and Pfizer look to establish a lead in the segment. Meanwhile, a second cancer candidate has been added to Codagenix's preclinical pipeline and data for its COVID-19 vaccine and TNBC oncolytic virus are expected next year, CEO Robert Coleman tells Scrip.
Getting Personal With Avail Medsystems’ Daniel Hawkins Who Has Entrepreneurship In His Blood And Recipes For Businesses And Kitchens
Medtech Insight’s new series Getting Personal features conversations with new and veteran senior executives about their journeys to corporate leadership, their motivations, passions and the peaks and valleys of running a medtech company. Daniel Hawkins, founder and CEO of Avail Medsystems discussed how his company virtually connects health care professionals into the operating suite and allows for real-time collaboration.
- Medical Devices
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Cardiovascular Dynamics, Inc.
- Nellix, Inc.
- PQ Bypass, Inc.
- Radiance Medical Systems, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.